Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichiro Yahiro

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Human Vaccines & Immunotherapeutics|December 28, 2020
Immunotherapy for osteosarcomaKenichiro Yahiro, Yoshihiro Matsumoto
Japanese Journal of Clinical Oncology|May 28, 2021
Clinical benefits of vessel sealing system (LigaSure™) during surgery for soft tissue sarcoma: a propensity score matching analysisEijiro Shimada, Yoshihiro Matsumoto, Makoto Endo, et al.
Current Treatment Options in Oncology|May 27, 2019
Diagnosis and Management of Subcutaneous Soft Tissue SarcomaMakoto Endo, Nokitaka Setsu, Toshifumi Fujiwara, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2020
Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytesKenichiro Yahiro, Yoshihiro Matsumoto, Hisakata Yamada, et al.
Analytical Cellular Pathology (Amsterdam)|July 24, 2018
Class III <i>β</i>-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell LineKenichiro Yahiro, Yoshihiro Matsumoto, Jun-Ichi Fukushi, et al.
Plos One|May 31, 2017
Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumorSuguru Fukushima, Makoto Endo, Yoshihiro Matsumoto, et al.
Plos One|March 16, 2018
Correction: Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumorSuguru Fukushima, Makoto Endo, Yoshihiro Matsumoto, et al.
Scientific Reports|August 4, 2022
Nuclear β-catenin translocation plays a key role in osteoblast differentiation of giant cell tumor of boneAtsushi Kimura, Yu Toda, Yoshihiro Matsumoto, et al.
British Journal of Cancer|January 12, 2022
Methylation-mediated silencing of protein kinase C zeta induces apoptosis avoidance through ATM/CHK2 inactivation in dedifferentiated chondrosarcomaEijiro Shimada, Yoshihiro Matsumoto, Makoto Nakagawa, et al.
Oncogene|August 14, 2019
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcomaMakoto Nakagawa, Fumihiko Nakatani, Hironori Matsunaga, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Human Vaccines & Immunotherapeutics|December 28, 2020
Immunotherapy for osteosarcomaKenichiro Yahiro, Yoshihiro Matsumoto
Japanese Journal of Clinical Oncology|May 28, 2021
Clinical benefits of vessel sealing system (LigaSure™) during surgery for soft tissue sarcoma: a propensity score matching analysisEijiro Shimada, Yoshihiro Matsumoto, Makoto Endo, et al.
Current Treatment Options in Oncology|May 27, 2019
Diagnosis and Management of Subcutaneous Soft Tissue SarcomaMakoto Endo, Nokitaka Setsu, Toshifumi Fujiwara, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2020
Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytesKenichiro Yahiro, Yoshihiro Matsumoto, Hisakata Yamada, et al.
Analytical Cellular Pathology (Amsterdam)|July 24, 2018
Class III <i>β</i>-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell LineKenichiro Yahiro, Yoshihiro Matsumoto, Jun-Ichi Fukushi, et al.
Plos One|May 31, 2017
Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumorSuguru Fukushima, Makoto Endo, Yoshihiro Matsumoto, et al.
Plos One|March 16, 2018
Correction: Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumorSuguru Fukushima, Makoto Endo, Yoshihiro Matsumoto, et al.
Scientific Reports|August 4, 2022
Nuclear β-catenin translocation plays a key role in osteoblast differentiation of giant cell tumor of boneAtsushi Kimura, Yu Toda, Yoshihiro Matsumoto, et al.
British Journal of Cancer|January 12, 2022
Methylation-mediated silencing of protein kinase C zeta induces apoptosis avoidance through ATM/CHK2 inactivation in dedifferentiated chondrosarcomaEijiro Shimada, Yoshihiro Matsumoto, Makoto Nakagawa, et al.
Oncogene|August 14, 2019
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcomaMakoto Nakagawa, Fumihiko Nakatani, Hironori Matsunaga, et al.
Pageof 1